Evidence map›Paper›PMID 41526543›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2026

Longitudinal analysis in Mecp2-het female mice reveals atypical nociceptive behaviours.

Javier Cuitavi, Elena Martínez-Rodríguez, María Abellán-Álvaro, Marina Rodríguez-Agut, Moisés García-Arencibia, Mónica Santos, Lucía Hipólito, Anabel Forte, Carmen Agustín-Pavón, Jose V Torres-Pérez

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Javier Cuitavi *School of Biochemistry and Immunology, Trinity College Dublin, Dublin, Ireland.ORCID http://orcid.org/0000-0003-3418-3135
Elena Martínez-Rodríguez *Departament de Biologia Cel·lular i Biologia Funcional, Universitat de València, C/Dr Moliner, 50. 46100, Burjassot, València, Spain.
María Abellán-ÁlvaroDepartament de Biologia Cel·lular i Biologia Funcional, Universitat de València, C/Dr Moliner, 50. 46100, Burjassot, València, Spain.ORCID http://orcid.org/0000-0001-8974-330X
Marina Rodríguez-AgutDepartament de Biologia Cel·lular i Biologia Funcional, Universitat de València, C/Dr Moliner, 50. 46100, Burjassot, València, Spain.
Moisés García-ArencibiaConsejería de Educación, Formación Profesional, Actividad Física y Deportes. Gobierno de Canarias, Las Palmas de Gran Canaria, Spain.ORCID http://orcid.org/0000-0002-1618-4487
Mónica SantosCNC - Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.ORCID http://orcid.org/0000-0003-3229-8270
Lucía HipólitoDepartment of Pharmacy and Pharmaceutical Technology and Parasitology, University of València, València, Spain.ORCID http://orcid.org/0000-0002-6834-5748
Anabel ForteDepartment of Statistics and Operations Research, Universitat de València, València, Spain.ORCID http://orcid.org/0000-0001-9534-1817
Carmen Agustín-PavónDepartament de Biologia Cel·lular i Biologia Funcional, Universitat de València, C/Dr Moliner, 50. 46100, Burjassot, València, Spain. m.carmen.agustin@uv.es.ORCID http://orcid.org/0000-0002-6725-6954
Jose V Torres-PérezDepartament de Biologia Cel·lular i Biologia Funcional, Universitat de València, C/Dr Moliner, 50. 46100, Burjassot, València, Spain. jose.vicente.torres@uv.es.ORCID http://orcid.org/0000-0001-6390-9690

Funding

British Pharmacological Society 2023 Pickford AwardConselleria de Educación, Cultura, Universidades y Empleo CIGE/2024/73Conselleria de Innovación, Universidades, Ciencia y Sociedad Digital, Generalitat Valenciana CIGE/2022/139)Dirección General de Ciencia e Investigación (Generalitat Valenciana) CIAICO/2022/165FinRett 02/2019FinRett 02/2022Ministerio de Ciencia e Innovación MCIN/AEI/10.13039/501100011033Ministerio de Ciencia e Innovación PID2019-107322GB-C22Ministerio de Ciencia e Innovación PID2022-137803NB-I00 funded by MCIN/AEI/10.13039/501100011033Ministerio de Ciencia e Innovación PID2022-138201NB-I00Ministerio de Ciencia e Innovación RYC2021-034012-IMinisterio de Universidades MS21-083PT2020-Centro CENTRO-01-0145-FEDER-000008Universitat de València UV-INV-PREDOC-1327981
6 · The paper itself

Abstract

Rett Syndrome (RTT), a neurodevelopmental disorder predominantly affecting females, is characterised by evolving symptoms impacting motor and sensory domains. Herein, we present a study of longitudinal analyses, from 2- to 6-month of age, of Mecp2 heterozygous (Mecp2-het) female mice to comprehensively explore pain perception in RTT. Interestingly, we found a significant variability in the timing and progression of symptom onset among Mecp2-het females, with individuals classified as either early- or late-symptomatic based on the emergence of hallmark neurological features such as clasping and gait abnormalities. This variability pinpoints the heterogeneity of the disease model and highlights the need to stratify Mecp2-het females by symptom onset in future studies to account for the diverse trajectories of disease progression. Additionally, our results reveal a shift from presymptomatic hypersensitivity in the von Frey test to apparent hyposensitivity, intricately linked with the onset of motor symptoms. Further, we found decreased neuronal activation in 6-month-old Mecp2-het females after the hot plate test in the periaqueductal grey, as measured by cFos expression, which does not happen with younger presymptomatic Mecp2-het females. Similarly, there is a lower expression of cannabinoid receptor 1 (CB1) in this area when compared to wild-type siblings. Taken together, our results suggest that both motor impairment and a possible dysregulation of endogenous analgesia might contribute to aberrant sensitivity in Mecp2-het mice. Our study emphasises the presymptomatic phase as crucial for understanding sensory abnormalities in Mecp2-het mice and highlights the challenges in identifying pain in RTT patients. KEY MESSAGES: Mecp2-het mice show early hypersensitivity to stimuli that shifts with age. Classification of Mecp2-het mice by symptom onset shows phenotypic variety. Mecp2-het mice show lower PAG activity when facing a thermal stimulus. Mecp2-het mice show decreased activity and CB1 receptor levels in the PAG.

Indexed as

Methyl-CpG-Binding Protein 2NociceptionRett SyndromeAnimalsBehavior, AnimalDisease Models, AnimalFemaleHeterozygoteLongitudinal StudiesMiceMice, Inbred C57BLReceptor, Cannabinoid, CB1Mecp2 protein, mouseMethyl-CpG-Binding Protein 2Receptor, Cannabinoid, CB1Endocannabinoid systemEndogenous analgesiaMecp2-het femalesNociceptionPainRett Syndrome

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.